PharmaFocus Today – Page 7 – media

Seilong Pharmaceutical’s subsidiary, Famotidine, receives approval for launching

Financial Update, January 1 – Seilong Pharmaceutical (002898) announced that its wholly-owned subsidiary, Hunan Seilong Pharmaceutical Co., Ltd., has recently received the approval notification for the listing application of Famotidine from the National Medical Products Administration. The valid period for this drug is 18 months, and the notification is effective until December 30, 2029, with a registration standard number of YBY77052024. Famotidine is primarily used to treat upper gastrointestinal bleeding caused by peptic ulcers, further enriching the company’s raw material pharmaceutical product pipeline. The company stated that specific production and sales conditions will be influenced by various internal and external environmental changes, which may lead to certain uncertainties. In the first three quarters of 2024, Seilong Pharmaceutical achieved revenue of 219 million yuan, with a net profit attributable to the parent company of -3.69 million yuan. https://finance.eastmoney.com/a/202501013284575136.html
- Source: drugdu
- 56
- January 6, 2025
The first generic version of the new dosage form of the “hematopoietic miracle drug” is released

On December 17, the Class 3 generic drug Eltrombopag ethanolamine dry suspension submitted by Zezheng Pharmaceutical was approved for marketing and deemed to have passed the review, becoming the first generic drug in China . Immune thrombocytopenia (ITP) is a common acquired bleeding disease. Platelets sensitized by platelet-specific autoantibodies are excessively destroyed by the mononuclear macrophage system, autoantibodies inhibit megakaryocytes from producing platelets and cytotoxicity, T cells directly lyse platelets, and antigen-specific T cell immune intolerance cause thrombocytopenia (<100×10^9/L). In clinical practice, glucocorticoids are the first-line drugs commonly used to treat ITP. However, since ITP is a chronic disease that requires long-term medication, the long-term use of glucocorticoids may produce a variety of adverse reactions. Eltrombopag is the world’s first small molecule non-peptide TPO receptor agonist approved for marketing. The drug can interact with the transmembrane domain of the human TPO receptor, initiate a signal cascade reaction, stimulate the proliferation ...
- Source: drugdu
- 49
- January 6, 2025
Yiming Biopharma Completes RMB 200 Million Pre-D Round Financing

Recently, Jiangsu Yiming Biotechnology Co., Ltd. (hereinafter referred to as “Yiming Biotechnology”) announced that it has successfully completed a new round of strategic financing of nearly 200 million yuan. This Pre-D round of financing was funded by Beijing Changping Industrial Development Investment Fund and Beijing Pharmaceutical and Health Industry The joint investment by the investment fund is another round of financing obtained by Yiming Bio after the C+ round of financing in April 2023. Yiming Bio said that as a bridge for ATMPs to go global and commercialize, it has received support from multiple investors in the current complex market environment. This round of financing will be used to further support the construction of Yiming Biopharma’s ATMPs CDMO commercial production base, promote technology iteration, enhance the service capabilities of the CDMO global service network, and consolidate the company’s core competitiveness in the ATMPs drug technology track. , creating a large ...
- Source: drugdu
- 49
- January 6, 2025
$135 million! Liraglutide is coming from China

Recently, Hanyu Pharmaceutical announced that its independently developed GLP-1 Liraglutide Injection has been approved by the FDA for marketing as the first generic version and has officially landed in the United States. As we all know, GLP-1 drugs have become the focus of the market in recent years due to their significant efficacy in reducing blood sugar and weight loss. However, precisely because of the skyrocketing demand, this type of drug has repeatedly faced problems of insufficient production and supply. The launch of Hanyu Pharmaceutical’s liraglutide generics in the U.S. market is not only an important breakthrough for Hanyu Pharmaceuticals in the international market, but also marks the imminent expansion of China’s liraglutide generics. Estimated peak sales of $135 million Liraglutide is a human glucagon-like peptide-1 (GLP-1) analog that can activate human GLP-1 receptors, promote insulin secretion, inhibit glucagon secretion, delay gastric emptying, and increase satiety, thereby reducing blood sugar ...
- Source: drugdu
- 60
- January 6, 2025
21 Health News Daily | The National Healthcare Security Administration will comprehensively promote strict supervision of drug traceability codes; The National Medical Products Administration approves the launch of China’s first stem cell therapy drug

The National Healthcare Security Administration will comprehensively promote strict supervision of drug traceability codes On January 2nd, the National Healthcare Security Administration issued a document clarifying the comprehensive promotion of “code based” strict supervision from January 1st, 2025. It will fully leverage the value of drug traceability code data, build various big data models, expand regulatory application scenarios, and carry out precise crackdowns on illegal and irregular use of medical insurance funds such as swapping and reselling medical insurance drugs, empty brushing and brushing medical insurance cards, and forging prescriptions, and increase the intensity of disposal. The drug traceability code is the only “electronic ID card” for drugs. In April 2024, the National Healthcare Security Administration launched a pilot project for the collection and application of drug traceability codes nationwide. In early November 2024, a public inquiry was conducted on 46 designated pharmaceutical institutions regarding the repeated reimbursement of a ...
- Source: drugdu
- 142
- January 4, 2025
Deeply focusing on the chronicity of tumors, Sinopharm is about to enter the harvest period of the global market

More convenient drug delivery methods, lower side effects, and higher survival rates… In the already booming field of anti-tumor drugs, there are still competitors constantly providing better solutions. Recently, the FDA approved the marketing of BMS’s Opdivo subcutaneous injection Opdivo Qvantig (nivolumab plus hyaluronidase), which also means that Opdivo is a latecomer, crossing the “KO battle” and becoming an earlier PD-1 subcutaneous formulation approved for marketing. Compared with the traditional intravenous infusion method that usually lasts for more than half an hour, subcutaneous preparations can be administered within 3-5 minutes, greatly improving patient comfort and convenience in medication. Of course, this administration method also has certain requirements for the difficulty of drug development. In September 2024, Roche also released a subcutaneous version of its PD-L1 antibody Tecentriq. It is worth noting that the subcutaneous formulation version of PD-L1 drugs does not come from multinational pharmaceutical companies, but from domestic innovative ...
- Source: drugdu
- 127
- January 4, 2025
SAP’s massive layoffs

According to foreign media reports, the world’s third-largest software company is undergoing large-scale layoffs. German software giant SAP, the world’s third-largest software company, is cutting 9000 to 10000 positions instead of the original 8000 positions. Among them, in Germany, plans are underway to lay off approximately 3500 out of 25000 employees through early retirement and layoffs, accounting for 14%. Insiders revealed that initially around 5300 people expressed interest in the plan. However, SAP rejected many applications to prevent the loss of critical technologies. Among the nearly 3500 approved volunteer employees, about 80% retired early, about 2800 people, and 20% received severance pay plans. Public information shows that SAP was founded in 1972 and was once ranked as the world’s third largest software company by Forbes magazine. The company is dedicated to SAP, an enterprise management software business, and its potential market competitor is the American company Oracle. In the field ...
- Source: drugdu
- 52
- January 4, 2025
Innovent Biologics and Roche have reached a global exclusive licensing agreement for the new generation of DLL3 antibody conjugated drugs

On January 2, 2025, San Francisco, USA and Suzhou, China – Xinda Biopharmaceutical Group (hereinafter referred to as “Xinda Biopharmaceutical”), a biopharmaceutical company dedicated to the research and development, production, and sales of innovative drugs in major disease fields such as oncology, autoimmune, cardiovascular and metabolic, and ophthalmology, announced today that it has reached a global exclusive cooperation and licensing agreement with Roche (SIX: RO, ROG; OTCQX: RHHBY) to promote the development of IBI3009, a new generation of antibody coupled drug (ADC) candidate products targeting Delta like ligand 3 (DLL3), aiming to provide a new treatment option for patients with advanced small cell lung cancer (SCLC). IBI3009 has currently obtained clinical application (IND) approval in Australia, China, and the United States, and the first patient in phase I clinical trials will be administered in December 2024. IBI3009： Potential best in class DLL3 ADC candidate drugs IBI3009 specifically targets DLL3, an ...
- Source: drugdu
- 140
- January 4, 2025
The bill “failed”, WuXi Biologics is back

WuXi Biologics is back. Since the progress of the US Biosafety Act has continued to jump sideways, WuXi Biologics’ stock price performance has been suppressed before September. As the company’s stock price rose to more than 3% today and closed up 2.19%, it not only outperformed the Hang Seng Index and Hang Seng Medical ETF, but the company’s overall recent trend has continued to improve (a cumulative increase of 58.21% since September 2024). This is due to the fact that the negative shoe finally landed. According to the latest news from the US House of Representatives bill, the Biosafety Act was not included in the 2025 NDAA (National Defense Security Act), which objectively confirmed the failure of the bill’s rapid legislation. In addition, according to recent news, the 2025 Continuing Appropriations and Extension Act (CR Act) announced by the US Congress also did not include the Biosafety Act. WuXi Biologics ...
- Source: drugdu
- 106
- January 4, 2025
A major breakthrough in solid tumor CAR-T, the key clinical success of domestic CAR-T therapy in the treatment of gastric cancer

On the morning of December 30, Keji Pharmaceutical (02171.HK) announced that China’s pivotal Phase II clinical trial of Serigene Oronza Injection for the treatment of advanced gastric/esophagogastric junction adenocarcinoma has obtained preliminary positive results. ▍About Sulgid Oronza Injection According to the announcement, this trial is a randomized controlled, multi-center clinical trial conducted in China, aiming to evaluate the treatment of Shuruiji Olense Injection (CT041) in the treatment of advanced patients with positive Claudin18.2 expression who have failed at least 2 lines of treatment in the past. Efficacy and safety in gastric/esophagogastric junction adenocarcinoma. The trial achieved its primary endpoint of progression-free survival (PFS) as assessed by an independent review committee (IRC). There was a statistically significant improvement in progression-free survival among subjects in the Serigen-Olenza injection group compared with the investigator’s choice treatment group. Previous test data shows that the safety of this product is controllable. Shuregen Orenza Injection is ...
- Source: drugdu
- 140
- January 4, 2025

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.